Oncorus is a biopharmaceutical company focused on developing viral immunotherapies to transform outcomes for cancer patients. Using its two platforms, the company develops a pipeline of intratumorally and intravenously administered product candidates designed to selectively attack and kill tumor cells and stimulate multiple arms of the immune system against tumors.
|HQ||Cambridge, MA, US||Map|
Net income (H1, 2020)
EBIT (H1, 2020)
Market capitalization (8-Feb-2021)
Closing stock price (8-Feb-2021)
|Company Name||Date||Deal Size|
|Oncorus Securities Corporation|
Oncorus has 359 Twitter Followers. The number of followers has increased 1.5% month over month and increased 4.7% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was Oncorus founded?
Oncorus was founded in 2015.
Who are Oncorus key executives?
Oncorus's key executives are Ted Ashburn, John McCabe and Mitchell H. Finer.
How many employees does Oncorus have?
Oncorus has 51 employees.
Who are Oncorus competitors?
Competitors of Oncorus include Invectys, Alpine Immune Sciences and Incanthera.
Where is Oncorus headquarters?
Oncorus headquarters is located at 50 Hampshire St #401, Cambridge.
Where are Oncorus offices?
Oncorus has an office in Cambridge.
How many offices does Oncorus have?
Oncorus has 1 office.
Receive alerts for 300+ data fields across thousands of companies